Journals / Anestezi Dergisi / 2019 / Cilt: 27 - Sayı: 2

Difficult Decision in Hereditary Hemoglobinopathies: Blood transfusion; when, how and why?

Kalıtsal Hemoglobinopatilerde Zor Karar: Kan Transfüzyonu; Ne Zaman, Nasıl, Niçin?

Pages
77–86
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, sickle cell anemia and thalassemia are treated as separate headings and the indications of perioperative transfusions applied to patients with hemoglobinopathy have been evaluated.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Sickle cell anemia and thalassaemia are the most common hereditary hemoglobinopathies in the world.
📊
Key Findings & Data:They course with chronic hemolytic anemia.
💡
Conclusion & Impact:In this review, sickle cell anemia and thalassemia are treated as separate headings and the indications of perioperative transfusions applied to patients with hemoglobinopathy have been evaluated.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Sickle cell anemia and thalassaemia are the most common hereditary hemoglobinopathies in the world. They course with chronic hemolytic anemia. These patients require intermittent blood transfusion for their quality of life. Multiple organ failure develops at an early age in these patients, who frequently experience problems in delivering oxygen to the tissue. The anesthetic management of these patients who have frequent side effects of blood transfusion and whose organ functions are at the limit is quite difficult and complicated. Unfortunately, no evidencebased, commonly shared opinion has been established about the amount of transfusion required and desired hemoglobin levels to reduce perioperative complications in these patients. The data available in the literature are derived from scarce number of randomized controlled trials and case reports, especially focused on the preoperative period. In this review, sickle cell anemia and thalassemia are treated as separate headings and the indications of perioperative transfusions applied to patients with hemoglobinopathy have been evaluated.

Özet

Orak hücreli anemi ve talasemi, dünyada en sık görülen kalıtsal hemoglobinopatilerdir. Kronik hemolitik anemi ile seyrederler. Yaşam kaliteleri için aralıklı kan transfüzyonuna gereksinim duyarlar. Sıklıkla dokuya oksijen sunumunda sorun yaşayan bu hastalarda erken yaşlarda çoklu organ yetmezlikleri gelişir. Kan transfüzyonunun yan etkilerini sık yaşayan ve organ fonksiyonları sınırda olan bu hastaların anestezi yönetimleri oldukça zor ve karmaşıktır. Ne yazık ki bugüne kadar hastalarda perioperatif komplikasyonların azaltılabilmesi açısından gerekli transfüzyon miktarı ve hemoglobin düzeyleri konusunda, kanıta dayalı, ortak bir görüş oluşturulamamıştır. Literatürde varolan veriler, özellikle preoperatif döneme odaklanmış, az sayıdaki randomize kontrollü çalışmalar ve olgu sunumlarıdır. Bu derlemede orak hücreli anemi ve talasemiler ayrı başlıklar halinde ele alınmış, hemoglobinopatili hastalara uygulanan perioperatif transfüzyonların gereklilikleri değerlendirilmeye çalışılmıştır.

🔖

Cite This Article

ATICI, Ş., ÖZDEMİR, L. (2019). Difficult Decision in Hereditary Hemoglobinopathies: Blood transfusion; when, how and why?. Anestezi Dergisi, Cilt: 27 - Sayı: 2, 77–86. https://ajindex.com/articles/146155

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Malik P. Gene Therapy for hemoglobinopathies: Tremendous successes and remaining caveats. Mol Ther. 2016;24:668-70. https://doi.org/10.1038/mt.2016.57
  2. Khurmi N, Gorlin A, Misra L. Perioperative considerations for patients with sickle cell disease: a narrative review. Can J Anaesth. 2017; 64:860-9. https://doi.org/10.1007/s12630-017-0883-3
  3. Modell B, Darlison MW, Moorthie S, Blencowe H, Petrou M, Lawn J. Epidemiologic methods in community genetics and model global database of congenital disorders, 2016.
  4. Tsaras G, Owusu-Ansah A, Boateng FO, AmoatengAdjepong Y. Complications associated with sickle cell trait: a brief narrative review. Am J Med. 2009;122:507-12. https://doi.org/10.1016/j.amjmed.2008.12.020
  5. Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions. PLoS Med. 2013;10:e1001484. https://doi.org/10.1371/journal.pmed.1001484
  6. Grosse SD, Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN. Sickle cell disease in Africa: a neglected cause of early childhood mortality. Am J Prev Med. 2011;41:398-405. https://doi.org/10.1016/j.amepre.2011.09.013 Lovaglio PG. Patient safety analysis linking claims and administrative data. Int J Health Care Qual Assur. 2012;25:698-711. https://doi.org/10.1108/09526861211270640
  7. Adjepong KO, Otegbeye F, Adjepong YA. Perioperative management of sickle cell disease. Mediterr J Hematol Infect Dis. 2018;10:e2018032. https://doi.org/10.4084/mjhid.2018.032
  8. Higgs DR, Engel JD, Stamatoyannopoulos G. Thalassaemia. Lancet. 2012;379:373-83. https://doi.org/10.1016/S0140-6736(11)60283-3
  9. Piga A, Serra M, Longo F, et al. Changing patterns of splenectomy in transfusion-dependent thalassemia patients. Am J Hematol. 2011;86:808-10. https://doi.org/10.1002/ajh.22102
  10. Ashley-Koch A, Yang Q, Olney RS. Sickle hemoglobin (Hb S) allele and sickle cell disease: a HuGE review. Am J Epidemiol. 2000;151:839-45. https://doi.org/10.1093/oxfordjournals.aje.a010288
  11. National Heart, Lung, and Blood Institute. Evidence-based management of sickle cell disease: expert panel report. Washington, DC: National Institutes of Health, 2014.
  12. McCurdy PR, Sherman AS. Irreversibly sickled cells and red cell survival in sickle cell anemia: a study with both DF32P and 51CR. Am J Med. 1978;64:253-8. https://doi.org/10.1016/0002-9343(78)90053-0
  13. Eadie GS, Brown IW. Analytical review: red blood cell survival studies. Blood. 1953;8:1110-36. Rei